AstraZeneca, Daiichi Will Seek Approval Following ADC Trial Success In Advanced Breast Cancer
Trastuzumab deruxtecan showed a clinically-meaningful response rate in patients with refractory HER2-positive metastatic breast cancer. • Source: Shutterstock
